Recombinant Human Noggin Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-3535
Recombinant Human Noggin Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-3535
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Tag | Fc |
Host Species | Human |
Accession | NP_005441.1 |
Synonym | Noggin, SYM1, SYNS1 |
Background | Noggin is a secreted protein involved at multiple stages of vertebrate embryonic development including neural induction and is known to exert its effects by inhibiting the bone morphogenetic protein (BMP)-signaling pathway. It binds several BMPs with very high (picomolar) affinities, with a marked preference for BMP2 and BMP4 over BMP7. By binding tightly to BMPs, Noggin prevents BMPs from binding their receptors. Noggin binds the bone morphogenetic proteins (BMP) such as BMP-4 and BMP-7, and inhibits BMP signaling by blocking the molecular interfaces of the binding epitopes for both type I and type II receptors. Interaction of BMP and its antagonist Noggin governs various developmental and cellular processes, including embryonic dorsal-ventral axis, induction of neural tissue, formation of joints in the skeletal system and neurogenesis in the adult brain. Noggin plays a key role in neural induction by inhibiting BMP4, along with other TGF-beta signaling inhibitors such as chordin and follistatin. Mouse knockout experiments have demonstrated that noggin also plays a crucial role in bone development, joint formation, and neural tube fusion. |
Description | A DNA sequence encoding the human Noggin precursor (NP_005441.1) (Met 1-Cys 232) was fused with the Fc region of human IgG1 at the C-terminus. |
Source | HEK293 |
Predicted N Terminal | Gln 28 |
AA Sequence | Met 1-Cys 232 |
Molecular Weight | The recombinant human Noggin/Fc is a disulfide-linked homodimeric protein after removal of the signal peptide. Each monomer comprises 443 a.a. and has a predicted molecular mass of 49.8 kDa. As a result of glycosylation, the apparent molecular mass of rhNoggin/Fc monomer is approximately 58-62 kDa in SDS-PAGE under reducing conditions. |
Purity | >95% as determined by SDS-PAGE |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Bioactivity | 1. Measured by its ability to inhibit BMP2-induced alkaline phosphatase production by MC3T3-E1 cells. The ED50 for this effect is typically 1.5-2.0 ug /mL in the presence of 0.25-0.5 ug/mL of BMP-2.2. Measured by its ability to inhibit BMP4-induced alkaline phosphatase production by MC3T3-E1 cells.The ED50 for this effect is typically 0.1-0.6 ug/mL in the presence of 50 ng/mL of hBMP4. |
Formulation | Lyophilized from sterile 100mM Glycine, 10mM NaCl, 50mM Tris, pH 7.5. |
Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
Usage | For Research Use Only |
Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |